๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia

โœ Scribed by Penelope J. Hallett; J.M. Brotchie


Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
279 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis


Enhanced delta opioid receptor transmission may represent an endogenous compensatory mechanism in parkinsonism to reduce the activity of the indirect striatopallidal pathway following dopamine depletion. Furthermore, increased delta opioid receptor transmission may be causative in the production of dyskinesia following repeated dopaminergic treatment in Parkinson's disease. The present study employed radioligand receptor autoradiography, using [ 3 H]naltrindole, a ligand selective for the delta opioid receptor, to assess delta opioid receptor binding sites in forebrain regions of reserpinetreated rats, and in parkinsonian nondyskinetic, and dyskinetic MPTP-lesioned macaques. In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (ฯฉ30%), sensorimotor striatum (ฯฉ20%), and associative stri-atum (ฯฉ17%) rostrally, but was not changed in caudal forebrain. In contrast, delta opioid receptor binding was not significantly altered at any region analyzed, in either nondyskinetic or dyskinetic, MPTP-lesioned macaques, compared to normal. These results suggest that transient changes in delta opioid receptor binding may occur in motor circuits following acute dopamine depletion. However, in the more chronic MPTPlesioned macaque model, simple changes in delta opioid receptor number or affinity are unlikely to contribute to mechanisms for abnormal opioid transmission in Parkinson's disease and dyskinesia.


๐Ÿ“œ SIMILAR VOLUMES


Computational cognitive models of prefro
โœ Ahmed A. Moustafa; Mark A. Gluck ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 462 KB

Disruption to different components of the prefrontal cortex, basal ganglia, and hippocampal circuits leads to various psychiatric and neurological disorders including Parkinson's disease (PD) and schizophrenia. Medications used to treat these disorders (such as levodopa, dopamine agonists, antipsych

The selective mu-opioid receptor antagon
โœ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following longโ€term treatment with 3,4โ€dihydroxyphenylalanine (Lโ€dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the

Stimulation of cannabinoid receptors red
โœ Susan H. Fox; Brian Henry; Michael Hill; Alan Crossman; Jonathan Brotchie ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 291 KB ๐Ÿ‘ 1 views

Long-term treatment with levodopa in Parkinson's disease results in the development of motor fluctuations, including reduced duration of antiparkinsonian action and involuntary movements, i.e., levodopa-induced dyskinesia. Cannabinoid receptors are concentrated in the basal ganglia, and stimulation

Effect of histamine H2 receptor antagoni
โœ Tom H. Johnston; Anne van der Meij; Jonathan M. Brotchie; Susan H. Fox ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 823 KB

## Abstract Levodopaโ€induced motor complications, including dyskinesia and wearing off, are troublesome side effects of treatment and impair quality of life in Parkinson's disease (PD) patients. The use of nondopaminergic agents as adjuncts to levodopa are potential options for managing these probl